What its response is regarding any impact on Scotland of reports that the UK Government will not procure the COVID-19 drug, Evusheld, to tr…

Throughout the pandemic, a UK-wide approach to the procurement of therapeutics has been vital to allow the UK to have the buying power to secure significant numbers of therapeutics in a competitive global market. This approach has ensured patients across the UK have had equal access to safe and effective medicines.
Evusheld ® was developed and tested before the emergence of the Omicron variant, and the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) conditional marketing authorisation outlined some remaining questions, including how effective Evusheld ® is against Omicron and the duration of its effect against current circulating variants. As a result, there is currently no established supply arrangement for Evusheld ® in the UK. The UK Health Security Agency (UKHSA) is carrying out further testing on the effectiveness of Evusheld ® against the Omicron variants which involve “live virus” tests taking place in the lab (“in vitro”). These tests are important because they provide certainty of the effectiveness of Evusheld ® against circulating variants and avoid the risk of introducing new variants through viral mutations.
The Scottish Government continues to closely monitor the outcome of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence.